GLP-1 drugs combined with healthy lifestyle habits linked to reduced cardiovascular risk among diabetes patients
Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.
Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
More than 200 participants enrolled as company targets topline data by end of 2026
Novo Nordisk Cuts Prices of Ozempic and Wegovy Starting January 2027
WEDNESDAY, Feb. 25, 2026 — Some of the most popular diabetes and weight-loss drugs in the U.S. will soon cost a lot less.
Novo Nordisk announced Tuesday that it will cut U.S. list prices of Ozempic and Wegovy by up to 50% starting next…
Why Some GLP-1 Users Say They’re Developing Scurvy
Reports of people developing scurvy while taking GLP-1 medications are on the rise. Milles Team/Shutterstock
Reports of GLP-1 users developing scurvy have increased in recent months.
GLP-1 drugs can lead to malnutrition since they reduce appetite and food consumption.
Semaglutide Not Linked to Depression Symptoms in People With HIV
(MedPage Today) — DENVER — People with HIV didn’t have a significant rise in depressive symptoms after starting semaglutide (Ozempic, Wegovy, Rybelsus) for diabetes or weight loss, according to a nine-site observational study.
After a median…
Novo Nordisk to slash Wegovy list price in half in 2027
Novo Nordisk said that starting next year, it will lower the list price of its popular GLP-1 products to $675 per month in a cost-cutting effort focused on patients with high insurance deductibles or copays …
Novo Nordisk Announces Significant Reduction in US List Price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), Building on Continued Efforts to Expand Access
Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide)…
Too Much Weight Loss With Retatrutide? Transgender Doc Sued; Ice Age Growth Disorder
(MedPage Today) — Some participants in a weight-loss trial of retatrutide, an investigational triple-hormone receptor agonist, dropped out because they thought they were losing too much weight. (New York Times)
Meanwhile, UBT251, another investigational…
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss
Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as much as 50%, while boasting Phase 2 data for its invesigational triple-G agonist.
Novo Nordisk to slash Wegovy and Ozempic prices starting in 2027
Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.